ALKERMES | ALKS - Ativo Circulante





Ativo Circulante Alterar Data
AbbVie USD 33.67B 140M 2026-06
Acadia Pharmaceuticals USD 1.22B 128.53M 2026-06
ALKERMES USD 1.52B 164.26M 2026-06
Amgen USD 34.96B 3.49B 2026-06
Biogen USD 7.31B 1.88B 2026-06
BioMarin Pharmaceutical USD 3.97B 633.45M 2026-06
Bristol-Myers Squibb USD 28.58B 1.37B 2026-06
Coherus Biosciences USD 133.79M 72.25M 2026-06
Eli Lilly USD 64.67B 9.84B 2026-06
Gilead Sciences USD 12.53B 6.11B 2026-06
Heron Therapeutics USD 229.84M 861K 2026-06
Ionis Pharmaceuticals USD 2.49B 446.73M 2026-06
J&J USD 59.77B 601M 2026-06
Malin Corporation EUR 62.6M 26.7M 2024-12
Merck USD 36.68B 1.66B 2026-06
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Nektar Therapeutics USD 589.04M 322.77M 2026-03
Neurocrine Biosciences USD 1.64B 798.6M 2026-06
Otsuka Holdings JPY 1.63T 30.58B 2026-06
Ovoca Bio EUR 2.07M 510K 2025-12
Pfizer USD 41.36B 1.46B 2026-06
Regeneron Pharmaceuticals USD 18.45B 236.8M 2026-06
Vertex Pharmaceuticals USD 12.54B 813.4M 2026-06